Target intelligence / Profile preview

Streptococcus pneumoniae capsular polysaccharide serotype 14 (CPS14) (CPS14)

Target
CPS14
Molecular classification
Other, Bacterial capsular polysaccharide, Bacterial surface antigen
01

Overview

Streptococcus pneumoniae capsular polysaccharide serotype 14 (CPS14) is a complex carbohydrate structure that forms the outermost protective layer of the serotype 14 pneumococcus bacterium. It serves as a primary virulence factor by acting as an antiphagocytic barrier that prevents host complement proteins from opsonizing the bacterial surface, thereby allowing the pathogen to evade destruction by phagocytic cells [1]. The chemical structure of CPS14 consists of a repeating tetrasaccharide unit containing glucose, galactose, and N-acetylglucosamine [2]. Due to its high prevalence in invasive pneumococcal diseases like pneumonia and meningitis, CPS14 is a critical antigenic component in multi-valent pneumococcal vaccines [3]. These vaccines, including conjugate and polysaccharide formulations, target CPS14 to induce the production of serotype-specific IgG antibodies [4]. These antibodies neutralize the capsule's protective effect, facilitating opsonophagocytosis and providing protective immunity against infections caused by this specific serotype [5]. Monitoring the efficacy of drugs targeting CPS14 typically involves measuring serotype-specific antibody concentrations and opsonophagocytic activity [4]. [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133335/ [2] https://pubmed.ncbi.nlm.nih.gov/11511295/ [3] https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924443/ [5] https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20

Other names
Pneumococcal polysaccharide serotype 14S. pneumoniae type 14 capsular polysaccharideSpn14 CPSType 14 pneumococcal polysaccharide
02

Mechanism of action

Induction of serotype-specific opsonizing antibodies that facilitate phagocytosis and clearance of Streptococcus pneumoniae serotype 14.

03

Biological functions

Immune responseOtherBacterial virulenceImmune evasion
04

Disease associations

Infection
05

Safety considerations

Serotype replacementHyporesponsivenessInjection site reactionsAnaphylaxis
06

Interacting drugs

Pneumococcal 13-valent conjugate vaccine (Prevnar 13)

4 more in the full profile.

07

Biomarkers

Serotype-specific IgG antibody concentrationOpsonophagocytic activity (OPA) titer

Beyond the preview

Go deeper on Streptococcus pneumoniae capsular polysaccharide serotype 14 (CPS14) (CPS14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide serotype 14 (CPS14) (CPS14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call